All Study Flyer
Click here (PDF) to search for a research study.
Research that Makes a Difference
The UC Davis MIND Institute supports critical research designed to understand the causes and to develop effective diagnoses, treatments, preventions, and ultimately, cures for neurodevelopmental disorders. Advances in neuroscience, molecular biology, genetics, pharmacology and behavioral sciences are making inroads into understanding brain function. The MIND Institute draws from these and other disciplines to conduct collaborative multidisciplinary research on specific neurodevelopmental disorders, including autism Spectrum Disorders, Down Syndrome, Fragile X Syndrome, Attention-Deficit/Hyperactivity Disorder (ADHD) and Chromosome 22q11.2 Deletion Syndrome.
The MIND Institute is uniquely positioned to take advantage of the outstanding expertise at UC Davis. The university offers robust programs in biological, environmental, medical and toxicological sciences.
The scope and impact of the Institute’s Research Program is exceptional. Studies ranging from basic biological studies to treatment trials, have lead to important contributions in such areas as synapse formation and plasticity, biomarkers research, evaluating startle responses, mouse model for autism, gene therapy of the brain, functions of the fragile X and MeCP2 genes, brain structure and the epidemiology of autism.
Highlighted Study of the Month
(RocDwn) A Study of the Efficacy, Safety and Tolerability of RO5186582 in Adults and adolescents with Down Syndrome
The goal of this study is to test the medication RO5186582 for improving learning, memory and language skills in individuals with Down syndrome. If you participate in this study you can expect: 10 visits to UC Davis MIND Institute including assessments given by our trained raters, blood and urine samples, ECGs, EEGs and randomization to receive either active medication or placebo.
Currently Enrolling: Individuals with Down syndrome, ages 12-30 years old. For more information about this study, contact Laura Berkowitz-Sutherland at (916) 703-0301.